Is Enzo Biochem, Inc. overvalued or undervalued?

As of 9 June 2022, the valuation grade for Enzo Biochem, Inc. moved from expensive to risky, indicating a significant shift in its perceived value. The company is currently assessed as overvalued based on its financial metrics. Key ratios include a Price to Book Value of 0.67, an EV to EBITDA of 1.12, and a negative ROE of -12.03%.
In comparison to peers, Enzo Biochem's P/E ratio is not applicable due to its loss-making status, while BioAtla, Inc. has a P/E of -0.3528 and an EV to EBITDA of 0.1364, illustrating the challenges faced by Enzo in maintaining competitiveness. Additionally, the company's recent stock performance has lagged significantly behind the S&P 500, with a year-to-date decline of 25.48% compared to a modest gain of 2.44% for the index. This further reinforces the conclusion that Enzo Biochem is overvalued in the current market environment.